A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

P.W. Zarutskie; James A. Phillips

doi:10.1016/j.fertnstert.2009.02.018

A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

P.W. Zarutskie, James A. Phillips

In: Fertility and Sterility · 2009 · vol. 92(1) , pp. 163–169 · doi:10.1016/j.fertnstert.2009.02.018 · PMID:19362303 · W2039002801

review OA: closed CC0 ⤵ 3 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This meta-analysis compared vaginal versus intramuscular progesterone for luteal phase support in assisted reproductive technology, evaluating its impact on outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (3)

References (43)

A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program via openalex
Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles via openalex
Use of Crinone∗ vaginal progesterone gel for luteal support in in vitro fertilization cycles via openalex
doi:10.1016/s0015-0282(01)02872-2 via openalex
doi:10.1016/j.fertnstert.2008.03.072 via openalex
doi:10.1016/s0015-0282(16)49949-8 via openalex
doi:10.1016/j.fertnstert.2008.02.012 via openalex
doi:10.1093/humrep/16.1.145 via openalex
doi:10.1016/s1472-6483(10)60597-4 via openalex
doi:10.1093/oxfordjournals.humrep.a137611 via openalex
doi:10.1007/s10815-007-9168-z via openalex
doi:10.1093/humupd/dmm021 via openalex
W2397550583 via openalex
W6603536631 via openalex
W6610091363 via openalex
W6662981737 via openalex
W6668215887 via openalex
W6673771426 via openalex
W6712511644 via openalex
doi:10.1097/00006250-200003000-00017 via openalex
doi:10.1016/j.fertnstert.2008.02.095 via openalex
doi:10.1016/s0301-2115(02)00010-6 via openalex
doi:10.1093/humrep/deg018 via openalex
doi:10.1016/s0015-0282(00)01158-4 via openalex
doi:10.1016/s0015-0282(00)01151-1 via openalex
doi:10.1080/j.0001-6349.2005.0854b.x via openalex
doi:10.3109/9780203092934-44 via openalex
doi:10.1002/14651858.cd004830 via openalex
doi:10.1016/s1726-4901(08)70088-1 via openalex
doi:10.1016/j.fertnstert.2006.05.067 via openalex
doi:10.1016/j.fertnstert.2007.03.006 via openalex
doi:10.1016/s0015-0282(00)01336-4 via openalex
doi:10.1081/ddc-200040251 via openalex
doi:10.1016/s0015-0282(03)01233-0 via openalex
doi:10.1016/s0015-0282(03)01221-4 via openalex
doi:10.1016/j.fertnstert.2008.07.456 via openalex
doi:10.1016/j.fertnstert.2008.02.035 via openalex
doi:10.1016/s0015-0282(97)00457-3 via openalex
doi:10.1093/humrep/15.6.1284 via openalex
W86560391 via openalex
doi:10.1016/j.fertnstert.2008.01.069 via openalex
W276193907 via openalex
doi:10.1016/s0015-0282(16)56758-2 via openalex

Cited by (3)

Source provenance

openalex: last seen: 2026-05-11T06:38:17.545654+00:00
unpaywall: last seen: 2026-06-02T02:00:03.124865+00:00

License: CC0 · commercial use OK

[1] A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program 1995

[2] Use of Crinone∗ vaginal progesterone gel for luteal support in in vitro fertilization cycles 1999

[3] Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles 1999